They found that the mutation order of TET2 and JAK2 V617F influenced the age when the MPN was diagnosed, the subclonal composition and proliferative capacity of flow cytometry defined HSPC in these patients, and the transcriptional profile of the malignant HSC (42). This evidence concerns the gene TET2 and myeloproliferative disorder.